BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

421 related articles for article (PubMed ID: 30842314)

  • 1. Sustained B cell depletion by CD19-targeted CAR T cells is a highly effective treatment for murine lupus.
    Kansal R; Richardson N; Neeli I; Khawaja S; Chamberlain D; Ghani M; Ghani QU; Balazs L; Beranova-Giorgianni S; Giorgianni F; Kochenderfer JN; Marion T; Albritton LM; Radic M
    Sci Transl Med; 2019 Mar; 11(482):. PubMed ID: 30842314
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic efficacy of anti-CD19 CAR-T cells in a mouse model of systemic lupus erythematosus.
    Jin X; Xu Q; Pu C; Zhu K; Lu C; Jiang Y; Xiao L; Han Y; Lu L
    Cell Mol Immunol; 2021 Aug; 18(8):1896-1903. PubMed ID: 32472023
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Autologous CD19-Targeted Chimeric Antigen Receptor (CAR)T-Cells as the Future of Systemic Lupus Erythematosus Treatment.
    Kambayana G; Surya Rini S
    Curr Rheumatol Rev; 2023 Jun; 19(3):260-269. PubMed ID: 36786138
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CAR-T Cell-Mediated B-Cell Depletion in Central Nervous System Autoimmunity.
    Gupta S; Simic M; Sagan SA; Shepherd C; Duecker J; Sobel RA; Dandekar R; Wu GF; Wu W; Pak JE; Hauser SL; Lim W; Wilson MR; Zamvil SS
    Neurol Neuroimmunol Neuroinflamm; 2023 Mar; 10(2):. PubMed ID: 36657993
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Closed-system manufacturing of CD19 and dual-targeted CD20/19 chimeric antigen receptor T cells using the CliniMACS Prodigy device at an academic medical center.
    Zhu F; Shah N; Xu H; Schneider D; Orentas R; Dropulic B; Hari P; Keever-Taylor CA
    Cytotherapy; 2018 Mar; 20(3):394-406. PubMed ID: 29287970
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CAR T-cell therapy in autoimmune diseases.
    Schett G; Mackensen A; Mougiakakos D
    Lancet; 2023 Nov; 402(10416):2034-2044. PubMed ID: 37748491
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted antibody-mediated depletion of murine CD19 CAR T cells permanently reverses B cell aplasia.
    Paszkiewicz PJ; Fräßle SP; Srivastava S; Sommermeyer D; Hudecek M; Drexler I; Sadelain M; Liu L; Jensen MC; Riddell SR; Busch DH
    J Clin Invest; 2016 Nov; 126(11):4262-4272. PubMed ID: 27760047
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An acquired defect in IgG-dependent phagocytosis explains the impairment in antibody-mediated cellular depletion in Lupus.
    Ahuja A; Teichmann LL; Wang H; Dunn R; Kehry MR; Shlomchik MJ
    J Immunol; 2011 Oct; 187(7):3888-94. PubMed ID: 21873531
    [TBL] [Abstract][Full Text] [Related]  

  • 9.
    Pfeiffer A; Thalheimer FB; Hartmann S; Frank AM; Bender RR; Danisch S; Costa C; Wels WS; Modlich U; Stripecke R; Verhoeyen E; Buchholz CJ
    EMBO Mol Med; 2018 Nov; 10(11):. PubMed ID: 30224381
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Murine models of systemic lupus erythematosus: B and T cell responses to spliceosomal ribonucleoproteins in MRL/Fas(lpr) and (NZB x NZW)F(1) lupus mice.
    Monneaux F; Dumortier H; Steiner G; Briand JP; Muller S
    Int Immunol; 2001 Sep; 13(9):1155-63. PubMed ID: 11526096
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential effect of allogeneic versus syngeneic mesenchymal stem cell transplantation in MRL/lpr and (NZB/NZW)F1 mice.
    Gu F; Molano I; Ruiz P; Sun L; Gilkeson GS
    Clin Immunol; 2012 Nov; 145(2):142-52. PubMed ID: 23041504
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A tandem CD19/CD20 CAR lentiviral vector drives on-target and off-target antigen modulation in leukemia cell lines.
    Schneider D; Xiong Y; Wu D; Nӧlle V; Schmitz S; Haso W; Kaiser A; Dropulic B; Orentas RJ
    J Immunother Cancer; 2017; 5():42. PubMed ID: 28515942
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Depletion of B cells in murine lupus: efficacy and resistance.
    Ahuja A; Shupe J; Dunn R; Kashgarian M; Kehry MR; Shlomchik MJ
    J Immunol; 2007 Sep; 179(5):3351-61. PubMed ID: 17709552
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of B Cell Depletion by CD19-Targeted Chimeric Antigen Receptor T Cells in a Murine Model of Systemic Sclerosis.
    Avouac J; Cauvet A; Orvain C; Boulch M; Tilotta F; Tu L; Thuillet R; Ottaviani M; Guignabert C; Bousso P; Allanore Y
    Arthritis Rheumatol; 2024 Feb; 76(2):268-278. PubMed ID: 37610259
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human CD19-Targeted Mouse T Cells Induce B Cell Aplasia and Toxicity in Human CD19 Transgenic Mice.
    Pennell CA; Barnum JL; McDonald-Hyman CS; Panoskaltsis-Mortari A; Riddle MJ; Xiong Z; Loschi M; Thangavelu G; Campbell HM; Storlie MD; Refaeli Y; Furlan SN; Jensen MC; Kean LS; Miller JS; Tolar J; Osborn MJ; Blazar BR
    Mol Ther; 2018 Jun; 26(6):1423-1434. PubMed ID: 29735365
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Construction and functional characterization of a fully human anti-CD19 chimeric antigen receptor (huCAR)-expressing primary human T cells.
    Mirzaei HR; Jamali A; Jafarzadeh L; Masoumi E; Alishah K; Fallah Mehrjardi K; Emami SAH; Noorbakhsh F; Till BG; Hadjati J
    J Cell Physiol; 2019 Jun; 234(6):9207-9215. PubMed ID: 30362586
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus.
    Mackensen A; Müller F; Mougiakakos D; Böltz S; Wilhelm A; Aigner M; Völkl S; Simon D; Kleyer A; Munoz L; Kretschmann S; Kharboutli S; Gary R; Reimann H; Rösler W; Uderhardt S; Bang H; Herrmann M; Ekici AB; Buettner C; Habenicht KM; Winkler TH; Krönke G; Schett G
    Nat Med; 2022 Oct; 28(10):2124-2132. PubMed ID: 36109639
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inducible Caspase-9 Selectively Modulates the Toxicities of CD19-Specific Chimeric Antigen Receptor-Modified T Cells.
    Diaconu I; Ballard B; Zhang M; Chen Y; West J; Dotti G; Savoldo B
    Mol Ther; 2017 Mar; 25(3):580-592. PubMed ID: 28187946
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Irradiated chimeric antigen receptor engineered NK-92MI cells show effective cytotoxicity against CD19
    Liu Q; Xu Y; Mou J; Tang K; Fu X; Li Y; Xing Y; Rao Q; Xing H; Tian Z; Wang M; Wang J
    Cytotherapy; 2020 Oct; 22(10):552-562. PubMed ID: 32747298
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial.
    Shah NN; Johnson BD; Schneider D; Zhu F; Szabo A; Keever-Taylor CA; Krueger W; Worden AA; Kadan MJ; Yim S; Cunningham A; Hamadani M; Fenske TS; Dropulić B; Orentas R; Hari P
    Nat Med; 2020 Oct; 26(10):1569-1575. PubMed ID: 33020647
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.